Cell Line Development Rentschler Biopharma, Atum Sign CDMO Licensing Agreement
Under the terms of the licensing agreement, Atum’s Leap-In Transposase technology will be integrated into Rentschler’s in-house process to complement its existing cell line development offering. The technology platform is ideal for the production of standard antibodies as well as complex, multi-chain therapeutic proteins.
Laupheim/Germany – Rentschler Biopharma, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, and Atum, a global specialist and industry leader in synthetic biology solutions, have recently announced the signing of a full CDMO licensing agreement for the Leap-In Transposase platform.
Under the terms of the agreement, Atum will provide Rentschler Biopharma full access to its Leap-In Transposase platform. The technology platform is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome.
The platform is particularly well suited for the production of standard antibodies as well as complex, multi-chain (e.g. 3+ chains) therapeutic proteins, such as bispecific monoclonal antibodies. Atum’s technology will strategically enhance Rentschler Biopharma’s cell line development services and capabilities and complement the existing service offered via the CDMO’s strategic partner network.
With this new collaboration, Rentschler Biopharma and Atum will be able to offer an additional service that will rapidly and robustly produce stable, high titer manufacturing cell lines, thereby supporting a growing number of organisations in moving their promising biopharmaceuticals to the market faster and with lower manufacturing risk than using alternative strategies.
Atum’s Leap-In Transposase platform will complement Rentschler Biopharma’s recently implemented CHO GS KO platform for difficult-to-express proteins by providing innovative and tailored solutions to translate complex medical research into outstanding biopharmaceuticals. Rentschler Biopharma’s integrated platform process will be well suited for high-quality protein expression and allow clients access to further robust and flexible approaches to designer protein therapeutics.
“At Rentschler Biopharma, we are always looking for innovative solutions across the entire value chain–from concept to market –by establishing strategic and valuable partnerships. We are excited to combine our knowledge and in-house cell line development process with the deep expertise of Atum, an industry leader in synthetic biology solutions for over a decade,” commented Dr. Frank Mathias, CEO of Rentschler Biopharma. “We want the best for our clients, and with the addition of Atum’s transformative Leap-In Transposase platform to our current service portfolio, we will be able to further support our clients in the development and production of complex next-generation biotherapeutics.”
Rentschler Biopharma and Atum share a long-term, strong commitment to innovation and excellence,” said Dr. Jeremy Minshull, CEO of Atum. “The Leap-In Transposase technology is revolutionising cell line development for simple as well as complex (multi-chain) therapeutic proteins and will provide Rentschler Biopharma stable, high-yield cell lines in very rapid timeframes. This capability adds another important instrument to their portfolio to accelerate time-to-market while maintaining product quality and reliability. We look forward to working with Rentschler Biopharma to support clients who are developing a wide variety of novel molecules.”